Nexdot, founded near Paris in 2010 and led by Benoit Dubertret, makes quantum plates, two-dimensional fluorescent nanocrystals, and encapsulates them in micro-pearls for uses from displays to cosmetics and medical devices. Its first EIC project, Nexdiag, promised "a highly multiplexed diagnostic test that will allow to assay IgE on 500 allergens (and up to 1000) at once using only one drop of blood", at 10 to 20 times lower cost, according to CORDIS. The EIC Fund lists Nexdot in its portfolio.
The European Innovation Council agreed to pay €2,500,000 towards a €3.63 million project planned from May 2023 to July 2026. CORDIS records that it was "terminated on 7 April 2026". The report lists "a validated library of 20 distinct optical barcodes", prototype kits, and a multiplex demonstration on patient samples covering 11 vaccine-related antigens. It says further uptake will need better production uniformity, batch reproducibility, sensitivity and "regulatory-grade validation on larger sample cohorts". In the May 2026 cut-off the EIC selected Nexdot again, for equity-only support for NEXSOLAR, quantum dots to capture "invisible" light in solar cells.
Company file
- Legal entity
- Nexdot SAS, SIREN 520 733 106, Romainville
- Founded
- 5 February 2010
- Leader
- Benoit Dubertret
- Technology
- Quantum plates encapsulated in micro-pearls
- Diagnostic partner
- Institut Pasteur
- EIC projects
- Nexdiag (2023 to 2026, terminated); NEXSOLAR (selected May 2026, equity only)
- EIC Fund
- Listed in portfolio
Where Nexdot Stands Now
Nexdot's EIC-backed work has moved from diagnostics to energy. The NEXSOLAR award aims to enhance "the efficiency of solar photovoltaic (PV) cells with quantum dots", according to the EIC's list of May 2026 selections. The company's website has not been updated with news since 2022. The French register shows it still active, with its 2025 accounts filed, according to Pappers.
"Further uptake will require continued optimisation of MicroPearl production uniformity, batch-to-batch reproducibility, assay sensitivity, quality control methods and regulatory-grade validation on larger sample cohorts."
Nexdot, report to the EICThe Technology: Colour-Coded Micro-Pearls
Each micro-pearl carries a unique fluorescent colour code and is coated with one allergen. When a patient's antibodies to that allergen bind, a green fluorescent reporter attaches too, and a flow cytometer reads which coloured pearls light up. The more distinct codes, the more allergens one test can check. The application said the test would sell for about €50, against €250 to €300 for current multiplex tests, and take less than 20 minutes.
What the EIC Project Promised, and What CORDIS Shows
The project promised to finish an allergy test covering 500 to 1,000 allergens, with the Institut Pasteur, and commercialise it to medical laboratories. It ended early with 20 barcodes and an 11-antigen demonstration in vaccine serology rather than allergy. No test reached the market. The report does not explain the termination.
- Barcode libraryPartly20 codes, not 1,000.
- Prototype kitsDeliveredAllergy and serology.
- 500-allergen testNot deliveredProject terminated.
- Market launchNot doneValidation still needed.
The Money
Nexdot's filed accounts show losses in each of the last four years, reaching €3.99 million in 2024 and €2.68 million in 2025, with €3.81 million in cash and €5.11 million of financial debt at the end of 2025. Its revenue is not shown in the summary. How much the EIC Fund invested and when has not been disclosed.
What Cannot Be Checked
Questions for the EIC
Why the Nexdiag project was terminated, how much of the grant was paid, how much the EIC Fund has invested and why the EIC selected Nexdot for a new, unrelated award a month later are not public.
Why Europe Should Care
A cheap test for hundreds of allergens at once would have helped the growing number of people with allergies. The EIC paid for most of the attempt, which fell far short. It has since backed the same company in a different market, while the public record says little about what the first award achieved.
What the project promised
A €50 blood test for up to 1,000 allergens, results in under 20 minutes.
What the record shows
A 20-code library, an 11-antigen demonstration, early termination and a new EIC bet on solar cells.
The Verdict
Allergy test abandoned, new bet placed
Nexdot did not deliver the diagnostic the EIC funded, and the project was cut short. The EIC has since chosen to back the company again in a different field.
Nexdot and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
